Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 192

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

GW9662, a potent antagonist of PPAR γ, inhibits growth of breast tumour cells and promotes the anticancer effects of the PPAR γ agonist rosiglitazone, independently of PPAR γ activation

Open access
Seargent, Jill M, Yates, Elisabeth A, Gill, Jason H · 2004 · British Journal of Pharmacology

Abstract

Peroxisome proliferator‐activated receptor gamma (PPAR γ), a member of the nuclear receptor superfamily, is activated by several compounds, including the thiazolidinediones. In addition to being a therapeutic target for obesity, hypolipidaemia and diabetes, perturbation of PPAR γ signalling is now believed to be a strategy for treatment of several cancers, including breast. Although differential expression of PPAR γ is observed in tumours compared to normal tissues and PPAR γ agonists have been shown to inhibit tumour cell growth and survival, the interdependence of these observations is unclear. This study demonstrated that the potent, irreversible and selective PPAR γ antagonist GW9662 prevented activation of PPAR γ and inhibited growth of human mammary tumour cell lines. Controversially, GW9662 prevented rosiglitazone‐mediated PPAR γ activation, but enhanced rather than reversed rosiglitazone‐induced growth inhibition. As such, these data support the existence of PPAR γ‐independent pathways and question the central belief that PPAR γ ligands mediate their anticancer effects via activation of PPAR γ. British Journal of Pharmacology (2004) 143, 933–937. doi:10.1038/sj.bjp.0705973

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/sj.bjp.0705973

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 192

Metadata

Authors
Seargent, J. M., Yates, E. A., & Gill, J. H.
Venue
British Journal of Pharmacology
Publisher
Wiley
Published
2004-12
Volume
143
Issue
8
Pages
933-937
ISSN
  • 0007-1188 (ISSN-L)
  • 1476-5381
OpenAlex
W2002276672
Cited by
192
References
3
FWCI
2.84
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: GW9662, a potent antagonist of PPAR γ, inhibits growth of breast tumour cells and promotes the anticancer effects of the PPAR γ agonist rosiglitazone, independently of PPAR γ activation. https://app.cochat.ai/papers/10.1038/sj.bjp.0705973
The paper
Seargent, J. M., Yates, E. A., & Gill, J. H. (2004). GW9662, a potent antagonist of PPAR γ, inhibits growth of breast tumour cells and promotes the anticancer effects of the PPAR γ agonist rosiglitazone, independently of PPAR γ activation. British Journal of Pharmacology. https://doi.org/10.1038/sj.bjp.0705973

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.